618 results match your criteria Prurigo Nodularis


[Translated article] Update on Chronic Prurigo.

Actas Dermosifiliogr 2022 Jun 28;113(6):T563-T574. Epub 2022 Apr 28.

Servicio de Dermatología, Hospital General Universitario de Alicante, Alicante, Spain.

Chronic prurigo is itself a common condition, but it can also occur secondary to a large number of diseases. Management is challenging as historically chronic prurigo has been poorly defined and very few treatments are available. Clinically, it presents as excoriated, hyperkeratotic lesions. Read More

View Article and Full-Text PDF

Successful treatment of refractory prurigo nodularis with baricitinib.

Dermatol Ther 2022 Jun 16:e15642. Epub 2022 Jun 16.

Zunyi Medical University, Zunyi, China.

View Article and Full-Text PDF

[[Translated article]]Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.

Actas Dermosifiliogr 2022 Jun 9. Epub 2022 Jun 9.

Servicio de Dermatología. Hospital General de Alicante, España.

Interleukin 31 (IL-31) is a neurocytokine that stimulates sensory neurons involved in pruritus. It contributes to skin barrier inflammation, dysfunction, and remodeling. As the immune and nervous systems are interrelated, IL-31 has a key role in the treatment of atopic dermatitis (AD) and prurigo nodularis (PN). Read More

View Article and Full-Text PDF

Dupilumab Significantly Reduces Symptoms of Prurigo Nodularis and Depression: A Case Series.

Acta Derm Venereol 2022 Jun 7. Epub 2022 Jun 7.

Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institutet, SE-171 76, Stockholm, Sweden.

View Article and Full-Text PDF

Abnormal keratin expression pattern in prurigo nodularis epidermis.

Skin Health Dis 2022 Mar 1;2(1):e75. Epub 2021 Dec 1.

Department of Dermatology Peking University Shenzhen Hospital Shenzhen Guangdong China.

Background: Prurigo nodularis (PN) is a highly pruritic, chronic dermatosis and difficult to treat. PN lesions are characterized by existence of many hyperkeratotic, erosive papules and nodules. However, the pathogenesis of PN still remains unelucidated. Read More

View Article and Full-Text PDF

Chronic prurigo.

Authors:
Laurent Misery

Br J Dermatol 2022 Jun 3. Epub 2022 Jun 3.

Univ Brest, LIEN, Brest, France.

Chronic prurigo is a distinct disease defined by the presence of chronic pruritus for at least 6 weeks, a history and/or signs of repeated scratching, and multiple localized or generalized pruritic skin lesions (whitish or pinkish papules, nodules and/or plaques). Although chronic prurigo is frequently named prurigo nodularis, the nodular type of chronic prurigo is only the main clinical aspect of chronic prurigo. Chronic prurigo occurs due to neural sensitization to pruritus and the development of a vicious pruritus-scratching cycle. Read More

View Article and Full-Text PDF

Post-Stroke Asymmetric Prurigo Nodularis Responding to Dupilumab Treatment: A Case Report.

Brain Sci 2022 May 5;12(5). Epub 2022 May 5.

Department of Health Sciences, Magna Graecia University, 88100 Catanzaro, Italy.

Prurigo nodularis (PN) is a dermatological condition characterized by nodular hyperkeratotic lesions mainly on the legs and arms. Asymmetrical PN is a rare dermatological condition often associated with paralysis and stroke. In this paper, we present the case of a 77-year-old woman who developed post-ictal PN which responded to dupilumab, an anti-interleukin-4/13 drug approved for the management of AD, with an extreme reduction in itch sensation. Read More

View Article and Full-Text PDF

Response to: "Racial disparities in mortality among patients with prurigo nodularis: A multi-center cohort study".

J Am Acad Dermatol 2022 May 13. Epub 2022 May 13.

Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Department of Dermatology, VA Integrated Service Network (VISN-1), Jamaica Plain, Massachusetts. Electronic address:

View Article and Full-Text PDF

Understanding racial disparities in prurigo nodularis.

J Am Acad Dermatol 2022 May 13. Epub 2022 May 13.

Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address:

View Article and Full-Text PDF

Immunotargets and Therapy for Prurigo Nodularis.

Immunotargets Ther 2022 26;11:11-21. Epub 2022 Apr 26.

Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, University of Miami Miller School of Medicine, Miami, FL, USA.

Prurigo nodularis is a chronic inflammatory skin disease consisting of severely pruritic nodules that can be very debilitating for patients. The basis of this skin condition is immunological dysregulation and neural amplification, driven by T-lymphocytes, mast cells, eosinophilic granulocytes, macrophages, and cytokines mediating itchy processes. Further complicating this already taxing diagnosis is the lack of approved treatment and consensus on management; although there are off-label treatments utilized as therapy. Read More

View Article and Full-Text PDF

Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications.

JAAD Int 2022 Jun 20;7:156-163. Epub 2022 Apr 20.

Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Introduction: Treating chronic pruritus is challenging for dermatologists due to the lack of therapeutic options. We review the effects of κ-opioid receptor (KOR) and μ-opioid receptor (MOR) in the modulation of itch, summarize evidence supporting the efficacy and safety of opioid receptor-targeting agents in chronic pruritus, and address clinical considerations.

Results: Preclinical studies have found neural pathways underlying detection, transmission, and modulation of itch signaling and spotlighted the importance of neuronal KOR and MOR in itch perception. Read More

View Article and Full-Text PDF

Case Report: Pemphigoid Nodularis-Five Patients With Many Years of Follow-Up and Review of the Literature.

Front Immunol 2022 12;13:885023. Epub 2022 Apr 12.

Department of Dermatology, Immunodermatology and Venereology, Medical University of Warsaw, Warsaw, Poland.

Pemphigoid nodularis is a rare form of pemphigoid that joins the clinical picture of prurigo nodularis and the immunological features of bullous pemphigoid, which is therapeutically challenging. Here, we analyze five female patients with a long-lasting course of nodular pemphigoid in terms of clinical and immunological characteristics and therapy. All the patients fulfilled clinical and immunological criteria of nodular pemphigoid. Read More

View Article and Full-Text PDF

Update on Chronic Prurigo.

Actas Dermosifiliogr 2022 Jun 16;113(6):563-574. Epub 2021 Nov 16.

Servicio de Dermatología, Hospital General Universitario de Alicante, Alicante, España.

Chronic prurigo is itself a common condition, but it can also occur secondary to a large number of diseases. Management is challenging as historically chronic prurigo has been poorly defined and very few treatments are available. Clinically, it presents as excoriated, hyperkeratotic lesions. Read More

View Article and Full-Text PDF

Prurigo Nodularis in a Patient with Anaplastic Large Cell Lymphoma: A Potential Role for M2-Macrophages in Its Pathogenesis.

Ann Dermatol 2022 Apr 24;34(2):149-151. Epub 2022 Mar 24.

Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

View Article and Full-Text PDF

Non-Atopic Chronic Nodular Prurigo (Prurigo Nodularis Hyde): A Systematic Review of Best-Evidenced Treatment Options.

Dermatology 2022 Apr 13:1-11. Epub 2022 Apr 13.

Department of Dermatology and Venerology, Aarhus University Hospital, Aarhus, Denmark.

Background: Chronic nodular prurigo (CNPG) is a chronic, inflammatory skin disease, characterized by intense and debilitating pruritus. The pathophysiology is not fully understood, and the condition is difficult to treat with no targeted therapies. The aim of this systematic review was to review the evidence of therapies for non-atopic CNPG and conduct a meta-analysis of the results. Read More

View Article and Full-Text PDF

Tofacitinib for Prurigo Nodularis: A Case Report.

Clin Cosmet Investig Dermatol 2022 21;15:503-506. Epub 2022 Mar 21.

Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.

Purpose: Despite recent advances in the treatment of prurigo nodularis, conventional treatment suffers from a dilemma of poor efficacy. The clinical use of Janus kinase (JAK) inhibitors in the treatment of Prurigo nodularis has rarely been explored.

Patients And Methods: We present a case of prurigo nodularis successfully treated with, JAK inhibitor tofacitinib with no adverse effects. Read More

View Article and Full-Text PDF

Dupilumab: A Safe and Successful Treatment in Refractory Prurigo Nodularis.

J Allergy Clin Immunol Pract 2022 05 21;10(5):1365-1366. Epub 2022 Mar 21.

Internal Medicine Department, Centro Hospitalar Universitário do Porto, Porto, Portugal; Clinical Immunology Unity, Centro Hospitalar Universitário do Porto, Porto, Portugal.

View Article and Full-Text PDF

Plasma Steroids and Endocannabinoids Used as Biomarkers to Assess the Pruritus Severity of Patients With Prurigo Nodularis.

Actas Dermosifiliogr 2022 Mar 1;113(3):T244-T253. Epub 2021 Nov 1.

School of Biological Sciences & Medical Engineering, Southeast University, Nanjing, China; Key Laboratory of Child Development and Learning Science (Southeast University), Ministry of Education, Nanjing, China; Institute of Child Development and Education, Southeast University, Nanjing, China. Electronic address:

Background: Prurigo nodularis (PN) as an extremely pruritic and hyperplastic chronic dermatosis induces psychologically and physiologically stressful responses. PN-induced responses in the hypothalamic-pituitary-adrenal, hypothalamic-pituitary-gonadal axes and endocannabinoid system are abnormal. Extant studies on the PN's pathogenesis mostly focused on the PN's psychological responses. Read More

View Article and Full-Text PDF

A Prospective Study Examining the Effect of Selected Topical and Systemic Drugs on Pruritus Grading System Score and STAT 6 Expression in Patients of Prurigo Nodularis.

Indian J Dermatol 2021 Nov-Dec;66(6):638-644

Department of Pathology, Atal Bihari Vajpayee Institute of Medical Sciences and Dr. Ram Manohar Lohia Hospital, New Delhi, India.

Background: Prurigo nodularis (PN) is a chronic dermatologic condition presenting as multiple papulonodular lesions occurring with intense pruritus. Though numerous agents (topical, systemic, phototherapy and biological drugs) have been tried, the outcomes are variable.

Objectives: The aim of this study was to assess the role of topical and systemic therapies in primary PN by comparing the Pruritus Grading System (PGS) score at baseline and 1 month post-therapy. Read More

View Article and Full-Text PDF

Abnormal Levels of Cortisol and Cortisone in Patients with Prurigo Nodularis.

Indian J Dermatol 2021 Nov-Dec;66(6):685-687

School of Biological Sciences and Medical Engineering, Southeast University, Nanjing, Jiangsu, China.

View Article and Full-Text PDF

The Association between Melatonin Levels and Sleep Quality in Patients with Pruritus: A Potential Biomarker on a Candidate Future Treatment.

Indian J Dermatol 2021 Nov-Dec;66(6):609-615

Department of Dermatology, Health Science University, Sisli Hamidiye Etfal Training and Research Hospital, istanbul, Turkey.

Background: Melatonin is a hormone that regulates the sleep-wake cycle and has immunomodulatory and anti-inflammatory roles.

Aims: The aim of this study is to assess melatonin levels and investigate the association with pruritus severity, sleep quality, and depressive symptoms in dermatoses with nocturnal pruritus.

Methods: The study was a prospective study with 82 participants, including 41 patients and 41 healthy volunteers. Read More

View Article and Full-Text PDF

Plasma Steroids and Endocannabinoids Used as Biomarkers to Assess the Pruritus Severity of Patients With Prurigo Nodularis.

Actas Dermosifiliogr 2022 Mar 8;113(3):244-253. Epub 2022 Feb 8.

School of Biological Sciences & Medical Engineering, Southeast University, Nanjing, China; Key Laboratory of Child Development and Learning Science (Southeast University), Ministry of Education, Nanjing, China; Institute of Child Development and Education, Southeast University, Nanjing, China. Electronic address:

Background: Prurigo nodularis (PN) as an extremely pruritic and hyperplastic chronic dermatosis induces psychologically and physiologically stressful responses. PN-induced responses in the hypothalamic-pituitary-adrenal (HPA), hypothalamic-pituitary-gonadal (HPG) axes and endocannabinoid system (ECS) are abnormal. Extant studies on the PN's pathogenesis mostly focused on the PN's psychological responses. Read More

View Article and Full-Text PDF

The emerging role of the neuroimmune cytokine interleukin-31 in chronic inflammatory skin diseases.

Ital J Dermatol Venerol 2022 Mar 11. Epub 2022 Mar 11.

Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy.

Chronic inflammatory skin diseases pose significant challenges for both patients and clinicians worldwide. Atopic dermatitis (AD), the most common of these diseases, affects up to 8% of the adult population depending on geographic location and demographic group, while prurigo nodularis (PN) is a less common disease that causes significant burden. In these inflammatory skin conditions, pruritus is a cardinal symptom. Read More

View Article and Full-Text PDF

Deranged integrin expression in the epidermis of pemphigoid nodularis and prurigo nodularis: Are they the same hyperproliferative state?

J Dermatol 2022 06 21;49(6):e203-e205. Epub 2022 Feb 21.

Department of Dermatology, Osaka City University Graduate School of Medicine, Osaka, Japan.

View Article and Full-Text PDF

Reversal of the disease signature in prurigo nodularis by blocking the itch cytokine.

Authors:
Enikö Sonkoly

J Allergy Clin Immunol 2022 Apr 18;149(4):1213-1215. Epub 2022 Feb 18.

Department of Medical Sciences, Uppsala University, Uppsala, Sweden; Dermatology and Venereology Division, Department of Medicine Solna, Karolinska Institutet, Solna, Sweden. Electronic address:

View Article and Full-Text PDF

Racial differences in dysregulation of the renin-angiotensin-aldosterone system in patients with prurigo nodularis.

J Dermatol Sci 2022 Feb 4;105(2):130-136. Epub 2022 Feb 4.

Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address:

Background: There are limited data characterizing the association between renal disease and prurigo nodularis (PN).

Objective: To characterize the association and describe mechanistic disease linkages between PN and renal comorbidities.

Methods: We conducted a cross-sectional analysis of renal comorbidities in PN using TriNetX, a global health research network providing access to medical records. Read More

View Article and Full-Text PDF
February 2022

Prurigo Nodularis.

Authors:
Shawn G Kwatra

JAMA Dermatol 2022 03;158(3):336

Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

View Article and Full-Text PDF

Epidemiology of prurigo nodularis in England: a retrospective database analysis.

Br J Dermatol 2022 Jan 26. Epub 2022 Jan 26.

Galderma SA, La Tour-de-Peilz, Switzerland.

Background: Prurigo nodularis is a debilitating skin condition that is classified as rare by the Genetic and Rare Diseases Information Center (GARD) and the National Organization for Rare Diseases (NORD). There are currently no estimates of the prevalence of prurigo nodularis in England.

Objectives: We aimed to address this data gap by describing the epidemiology of prurigo nodularis in a representative dataset derived from the English National Health Service. Read More

View Article and Full-Text PDF
January 2022